Aktuellt
SENASTE
Redeye endorses ISAB presenting positive topline data from its clinical study. With these results in place, new market opportunities worth more than SEK 5bn arise. We maintain our positive long-term view and continue to argue that the share offers an attractive risk/reward at current share price levels.
LÄS MER
